408 related articles for article (PubMed ID: 25660553)
21. The emerging understanding of myeloid cells as partners and targets in tumor rejection.
Broz ML; Krummel MF
Cancer Immunol Res; 2015 Apr; 3(4):313-9. PubMed ID: 25847968
[TBL] [Abstract][Full Text] [Related]
22. Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression.
Awad RM; De Vlaeminck Y; Maebe J; Goyvaerts C; Breckpot K
Front Immunol; 2018; 9():1977. PubMed ID: 30233579
[TBL] [Abstract][Full Text] [Related]
23. Microbes and Cancer.
Dzutsev A; Badger JH; Perez-Chanona E; Roy S; Salcedo R; Smith CK; Trinchieri G
Annu Rev Immunol; 2017 Apr; 35():199-228. PubMed ID: 28142322
[TBL] [Abstract][Full Text] [Related]
24. Myeloid Cell-Derived Oxidized Lipids and Regulation of the Tumor Microenvironment.
Hicks KC; Tyurina YY; Kagan VE; Gabrilovich DI
Cancer Res; 2022 Jan; 82(2):187-194. PubMed ID: 34764204
[TBL] [Abstract][Full Text] [Related]
25. Molecular Pathways: Targeting Tumor-Infiltrating Myeloid-Derived Suppressor Cells for Cancer Therapy.
Di Mitri D; Toso A; Alimonti A
Clin Cancer Res; 2015 Jul; 21(14):3108-12. PubMed ID: 25967145
[TBL] [Abstract][Full Text] [Related]
26. Targeting myeloid cells in the tumor sustaining microenvironment.
Schupp J; Krebs FK; Zimmer N; Trzeciak E; Schuppan D; Tuettenberg A
Cell Immunol; 2019 Sep; 343():103713. PubMed ID: 29129292
[TBL] [Abstract][Full Text] [Related]
27. Intestinal microbiota: unexpected alliance with tumor therapy.
Mukaida N
Immunotherapy; 2014; 6(3):231-3. PubMed ID: 24762069
[TBL] [Abstract][Full Text] [Related]
28. Tumor-associated myeloid cells: new understandings on their metabolic regulation and their influence in cancer immunotherapy.
Porta C; Sica A; Riboldi E
FEBS J; 2018 Feb; 285(4):717-733. PubMed ID: 28985035
[TBL] [Abstract][Full Text] [Related]
29. Myeloid cells in cancer-related inflammation.
Caronni N; Savino B; Bonecchi R
Immunobiology; 2015 Feb; 220(2):249-53. PubMed ID: 25454487
[TBL] [Abstract][Full Text] [Related]
30. Myeloid regulatory cells in tumor spreading and metastasis.
Keskinov AA; Shurin MR
Immunobiology; 2015 Feb; 220(2):236-42. PubMed ID: 25178934
[TBL] [Abstract][Full Text] [Related]
31. Myeloid cell heterogeneity in cancer: not a single cell alike.
Kiss M; Van Gassen S; Movahedi K; Saeys Y; Laoui D
Cell Immunol; 2018 Aug; 330():188-201. PubMed ID: 29482836
[TBL] [Abstract][Full Text] [Related]
32. Cancer-induced systemic myeloid dysfunction: Implications for treatment and a novel nanoparticle approach for its correction.
Alvarez R; Oliver L; Valdes A; Mesa C
Semin Oncol; 2018 Jan; 45(1-2):84-94. PubMed ID: 30318088
[TBL] [Abstract][Full Text] [Related]
33. Immunosuppressive cells and tumour microenvironment: focus on mesenchymal stem cells and myeloid derived suppressor cells.
Bianchi G; Borgonovo G; Pistoia V; Raffaghello L
Histol Histopathol; 2011 Jul; 26(7):941-51. PubMed ID: 21630223
[TBL] [Abstract][Full Text] [Related]
34. Tolerance and immune suppression in the tumor microenvironment.
Ostrand-Rosenberg S
Cell Immunol; 2016 Jan; 299():23-9. PubMed ID: 26435343
[TBL] [Abstract][Full Text] [Related]
35. Toll-Like Receptor 2 at the Crossroad between Cancer Cells, the Immune System, and the Microbiota.
Di Lorenzo A; Bolli E; Tarone L; Cavallo F; Conti L
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33321934
[TBL] [Abstract][Full Text] [Related]
36. Innate lymphoid cells, possible interaction with microbiota.
Moro K; Koyasu S
Semin Immunopathol; 2015 Jan; 37(1):27-37. PubMed ID: 25502370
[TBL] [Abstract][Full Text] [Related]
37. Metabolic influence on the differentiation of suppressive myeloid cells in cancer.
Porta C; Marino A; Consonni FM; Bleve A; Mola S; Storto M; Riboldi E; Sica A
Carcinogenesis; 2018 Sep; 39(9):1095-1104. PubMed ID: 29982315
[TBL] [Abstract][Full Text] [Related]
38. Lipid Metabolism and Cancer Immunotherapy: Immunosuppressive Myeloid Cells at the Crossroad.
Bleve A; Durante B; Sica A; Consonni FM
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32823961
[TBL] [Abstract][Full Text] [Related]
39. Myeloid suppressor cells in cancer and autoimmunity.
Sica A; Massarotti M
J Autoimmun; 2017 Dec; 85():117-125. PubMed ID: 28728794
[TBL] [Abstract][Full Text] [Related]
40. Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche.
Asimakopoulos F; Hope C; Johnson MG; Pagenkopf A; Gromek K; Nagel B
J Leukoc Biol; 2017 Aug; 102(2):265-275. PubMed ID: 28254840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
